Robert S. Goodwin

5.3k total citations · 2 hit papers
38 papers, 4.0k citations indexed

About

Robert S. Goodwin is a scholar working on Pharmacology, Toxicology and Clinical Psychology. According to data from OpenAlex, Robert S. Goodwin has authored 38 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pharmacology, 23 papers in Toxicology and 10 papers in Clinical Psychology. Recurrent topics in Robert S. Goodwin's work include Cannabis and Cannabinoid Research (29 papers), Forensic Toxicology and Drug Analysis (23 papers) and Psychedelics and Drug Studies (10 papers). Robert S. Goodwin is often cited by papers focused on Cannabis and Cannabinoid Research (29 papers), Forensic Toxicology and Drug Analysis (23 papers) and Psychedelics and Drug Studies (10 papers). Robert S. Goodwin collaborates with scholars based in United States, France and Germany. Robert S. Goodwin's co-authors include T.M. Savege, Michael A. E. Ramsay, B. R. Simpson, Marilyn A. Huestis, David A. Gorelick, Erin L Karschner, Marilyn A. Huestis, Jussi Hirvonen, W. D. Darwin and Allan J. Barnes and has published in prestigious journals such as PLoS ONE, Clinical Chemistry and Biochemical Pharmacology.

In The Last Decade

Robert S. Goodwin

37 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Controlled Sedation with Alphaxalone-Alphadolone

1974 2.2k citations Michael A. E. Ramsay, T.M. Savege et al. BMJ profile →
Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers

2011 424 citations Jussi Hirvonen, Robert S. Goodwin et al. Molecular Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert S. Goodwin United States	23	1.6k	1.4k	973	760	737	38	4.0k
Ola Dale Norway	39	1.9k 1.2×	715 0.5×	328 0.3×	118 0.2×	727 1.0×	136	4.5k
Elise Sarton Netherlands	43	2.1k 1.3×	1.4k 1.0×	262 0.3×	129 0.2×	925 1.3×	101	5.4k
Leon Aarts Netherlands	40	1.5k 0.9×	990 0.7×	545 0.6×	75 0.1×	1.5k 2.0×	115	4.9k
Marieke Niesters Netherlands	38	1.3k 0.8×	1.5k 1.1×	178 0.2×	98 0.1×	806 1.1×	126	4.1k
J Kanto Finland	36	2.3k 1.4×	471 0.3×	595 0.6×	54 0.1×	1.4k 1.9×	245	4.9k
Theodore H. Stanley United States	41	3.2k 2.0×	279 0.2×	622 0.6×	168 0.2×	2.0k 2.7×	209	5.5k
Walter L. Way United States	26	1.6k 1.0×	676 0.5×	345 0.4×	45 0.1×	741 1.0×	61	3.4k
Robert A. Whittington United States	29	601 0.4×	203 0.1×	1.1k 1.1×	65 0.1×	198 0.3×	68	2.7k
JOHN W. DUNDEE United Kingdom	42	3.4k 2.2×	685 0.5×	623 0.6×	50 0.1×	2.2k 3.0×	334	7.1k
James G. Bovill Netherlands	43	3.0k 1.9×	467 0.3×	701 0.7×	55 0.1×	2.1k 2.8×	190	5.4k

Countries citing papers authored by Robert S. Goodwin

Since Specialization

Citations

This map shows the geographic impact of Robert S. Goodwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Goodwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Goodwin more than expected).

Fields of papers citing papers by Robert S. Goodwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Goodwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Goodwin. The network helps show where Robert S. Goodwin may publish in the future.

Co-authorship network of co-authors of Robert S. Goodwin

This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Goodwin. A scholar is included among the top collaborators of Robert S. Goodwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Goodwin. Robert S. Goodwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desrosiers, Nathalie A., Allan J. Barnes, Rebecca L. Hartman, et al.. (2013). Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration. Analytical and Bioanalytical Chemistry. 405(12). 4067–4076. 18 indexed citations

Hartman, Rebecca L., Nathalie A. Desrosiers, Allan J. Barnes, et al.. (2013). 3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration. Analytical and Bioanalytical Chemistry. 406(2). 587–599. 20 indexed citations

Bosker, Wendy M., Erin L Karschner, Dayong Lee, et al.. (2013). Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. PLoS ONE. 8(1). e53127–e53127. 58 indexed citations

Himes, Sarah K., Robert S. Goodwin, Hendrée E. Jones, et al.. (2012). Methadone and Metabolites in Hair of Methadone-Assisted Pregnant Women and Their Infants. Therapeutic Drug Monitoring. 34(3). 337–344. 14 indexed citations

Karschner, Erin L, David M. Schwope, Eugene W Schwilke, et al.. (2012). Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug and Alcohol Dependence. 125(3). 313–319. 35 indexed citations

Gorelick, David A., Robert S. Goodwin, Eugene W Schwilke, et al.. (2012). Tolerance to Effects of High-Dose Oral Δ9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. Journal of Analytical Toxicology. 37(1). 11–16. 62 indexed citations

Lee, Dayong, Erin L Karschner, Garry Milman, et al.. (2012). Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. Drug and Alcohol Dependence. 130(1-3). 68–76. 26 indexed citations

Hirvonen, Jussi, Robert S. Goodwin, Cheng‐Ta Li, et al.. (2011). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry. 17(6). 642–649. 424 indexed citations breakdown →

Gorelick, David A., Robert S. Goodwin, Eugene W Schwilke, et al.. (2011). Antagonist-Elicited Cannabis Withdrawal in Humans. Journal of Clinical Psychopharmacology. 31(5). 603–612. 12 indexed citations

10.

Schwaninger, Andrea E., Markus R. Meyer, Allan J. Barnes, et al.. (2011). Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochemical Pharmacology. 83(1). 131–138. 19 indexed citations

11.

Milman, Garry, Allan J. Barnes, David M. Schwope, et al.. (2011). Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry. 401(2). 599–607. 25 indexed citations

12.

Schwaninger, Andrea E., Markus R. Meyer, Allan J. Barnes, et al.. (2011). Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration. Clinical Chemistry. 57(12). 1748–1756. 25 indexed citations

13.

Barnes, Allan J., Richie H. Lowe, Garry Milman, et al.. (2009). Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans. Journal of Analytical Toxicology. 33(8). 439–446. 44 indexed citations

14.

Kolbrich, Erin A, Robert S. Goodwin, David A. Gorelick, et al.. (2008). Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young Adults. Therapeutic Drug Monitoring. 30(3). 320–332. 90 indexed citations

15.

Kolbrich, Erin A, Robert S. Goodwin, David A. Gorelick, et al.. (2008). Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine Administration. Journal of Clinical Psychopharmacology. 28(4). 432–440. 57 indexed citations

16.

Goodwin, Robert S., et al.. (2008). Urinary Elimination of 11-Nor-9-Carboxy- 9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence. Journal of Analytical Toxicology. 32(8). 562–569. 84 indexed citations

17.

Goodwin, Robert S., et al.. (2006). ??9-Tetrahydrocannabinol, 11-Hydroxy-??9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-??9-Tetrahydrocannabinol in Human Plasma After Controlled Oral Administration of Cannabinoids. Therapeutic Drug Monitoring. 28(4). 545–551. 37 indexed citations

18.

Brophy, Mary T., et al.. (1994). Comparison of a Standard and a Sensitive Thromboplastin in Monitoring Low Intensity Oral Anticoagulant Therapy. American Journal of Clinical Pathology. 102(1). 134–137. 6 indexed citations

19.

Goodwin, Robert S., et al.. (1984). A General Use of Amberlite XAD-2 Resin for the Purification of Flavonoids from Aqueous Fractions. Journal of Natural Products. 47(1). 188–188. 15 indexed citations

20.

Ramsay, Michael A. E., T.M. Savege, B. R. Simpson, & Robert S. Goodwin. (1974). Controlled Sedation with Alphaxalone-Alphadolone. BMJ. 2(5920). 656–659. 2151 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact